The Procalcitonin And Survival Study (PASS) - a randomised multi-center investigator-initiated trial to investigate whether daily measurements biomarker Procalcitonin and pro-active diagnostic and therapeutic responses to abnormal Procalcitonin levels, can improve survival in intensive care unit patients. Calculated sample size (target population): 1000 patients

Jens-Ulrik Jensen, Bettina Lundgren, Lars Hein, Thomas Mohr, Pernille L Petersen, Lasse H Andersen, Anne O Lauritsen, Sine Hougaard, Teit Mantoni, Bonnie Bømler, Klaus J Thornberg, Katrin Thormar, Jesper Løken, Morten Steensen, Peder Carl, J Asger Petersen, Hamid Tousi, Peter Søe-Jensen, Morten Bestle, Søren HestadMads H Andersen, Paul Fjeldborg, Kim M Larsen, Charlotte Rossau, Carsten B Thomsen, Christian Ostergaard, Jesper Kjaer, Jesper Grarup, Jens D Lundgren

35 Citationer (Scopus)

Abstract

Udgivelsesdato: 2008-null
OriginalsprogEngelsk
TidsskriftBMC Infectious Disease
Vol/bind8
Sider (fra-til)91
DOI
StatusUdgivet - 2008

Fingeraftryk

Dyk ned i forskningsemnerne om 'The Procalcitonin And Survival Study (PASS) - a randomised multi-center investigator-initiated trial to investigate whether daily measurements biomarker Procalcitonin and pro-active diagnostic and therapeutic responses to abnormal Procalcitonin levels, can improve survival in intensive care unit patients. Calculated sample size (target population): 1000 patients'. Sammen danner de et unikt fingeraftryk.

Citationsformater